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 MicroRNAs (miRNAs) are small (~20-22 nucleotides) non-coding RNAs able to regulate 
gene expression through repression or degradation of mRNAs.1 MiRNAs are the biggest class of 
genetic regulators and they act at a post-transcriptional level with a mechanism based on sequence 
complementarities between miRNA and target messenger RNA (mRNA) (Figure 1).2 MiRNAs are 
important regulator of the principal cell functions including growth, proliferation, differentiation 
and apoptosis, being involved in the oncogenic processes acting as oncogenes, tumor suppressor 
genes or both.3 In addition, there is a growing interest to explore circulating miRNAs as potential 
biomarkers for early hepatocellular carcinoma (HCC) detection.4 
Sun et al. observed an increased expression of miR-9 (i.e. miR-9-5p) in HCC tissue 
compared to normal liver and adjacent non-cancerous tissues; higher miR-9 expression was 
associated with a poor prognosis of HCC.5 Furthermore, it has been reported that miR-9 could 
promote tumour cell migration and invasion in HCC cell lines.6  
Recently, Tang et al investigated the biological function of exosomal miR-9-3p (the “minor” 
product of miR-9) with a focus on its involvement in the proliferation of HCC cells.7 Interestingly, 
in an experimental model authors observed that miR-9-3p, as miR-9, is overexpressed in HCC cell 
lines, but showing opposite biological effects. Indeed, miR-9-3p was able to inhibit HCC cells 
proliferation by directly suppressing heparin-binding growth factor-5 (HBGF-5) expression, a gene 
member of the fibroblast growth factor (FGF) family,8 and by inhibiting the extracellular signal-
regulated protein kinase 1 and 2 (ERK1/2) expression, involved in the regulation mechanism of cell 
proliferation and apoptosis.9 
In addition, Tang et al found that miR-9-3p levels were significantly higher in the serum 
exosomes of normal donors compared to patients with HCC. The accuracy for the discrimination 
between donors and HCC patients was 0.813 (area under the curve) indicating a good diagnostic 
performance for miR-9-3p.7 To date, several studies assessed the potential role of miRNAs as well 
as other classes of biomarkers for HCC detection and reported promising results.1, 10-13 However, 
must be stressed that caution should be used when dealing with miRNAs and other epigenetic 
molecules,14, 15 since the complex miRNA-mRNA interaction may be affected by numerous other 
genetic and epigenetic features, consequently resulting in an alteration of miRNAs expression.16 In 
addition, the use of such molecules as cancer biomarkers is partly limited by lack of standardized 
method for their quantitation. Since there is still a need of reliable biomarkers for HCC detection, 
the use of traditional biomarkers assessed by novel highly sensitive and fully automated analytical 
methods, may be the most effective strategy to address this clinically relevant issue. 
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Figure 1.-Biogenesis and function of miRNAs. 
 
MiRNAs are transcribed in the nucleus by RNA polymerase II as a stem-loop primary transcript 
(pri-miRNAs). Following a cleavage by the ribonuocleoprotein complex Drosha/DGCR8, hairpin 
precursor-miRNAs (pre-miRNAs) are exported into the cytoplasm through exportin-5. Then, pre-
miRNAs are further processed by another RNAse III (Dicer) into an RNA-duplex consisting of the 
mature miRNA and the passenger miRNA strand. Subsequently, miRNA duplex is unwinded by 
helicase activity and the mature miRNA (arisen from the 5’ arm) can be incorporated into the RNA-
induced silencing complex (RISC). Usually, the “minor” passenger strand (arisen from the 3’ arm) 
is not functional and cannot be incorporated into the RISC complex. The miRNA-RISC complex 
allow the interaction between the mature miRNA and the target mRNA. According to miRNA-
mRNA complementarity, their interaction induces either mRNA translation repression or mRNA 
degradation.  
Abbreviations: miRNA, microRNA; RISC, RNA-induced silencing complex. 
